Brain tumours (primary) and brain metastases in adults

Consultation on draft guideline – deadline for comments: 5pm on 23/02/2018, email: PrimaryBrainTumours@nice.org.uk

Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.

We would like to hear your views on the draft recommendations presented in the short version and any comments you may have on the evidence presented in the full version. We would also welcome views on the Equality Impact Assessment.

We would like to hear your views on these questions:
1. Which areas will have the biggest impact on practice and be challenging to implement? Please say for whom and why.
2. Would implementation of any of the draft recommendations have significant cost implications?
3. What would help users overcome any challenges? (For example, existing practical resources or national initiatives, or examples of good practice.)
4. [Insert any specific questions about the recommendations from the Developer, or delete if not needed]

See section 3.9 of Developing NICE guidance: how to get involved for suggestions of general points to think about when commenting.

<table>
<thead>
<tr>
<th>Organisation name – Stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please leave blank):</th>
<th>[British HIV Associations (BHIVA)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disclosure</td>
<td>[None]</td>
</tr>
</tbody>
</table>

Please return to: PrimaryBrainTumours@nice.org.uk
Name of commentator person completing form: **Professor Mark Bower**

<table>
<thead>
<tr>
<th>Comment number</th>
<th>Document (GL for guideline; A, B etc for evidence report, 1, 2 etc for supplementary document)</th>
<th>Page number</th>
<th>Line number</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>GL 16 45</td>
<td>We are concerned that this recommendation may imply that</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GL 16 45</td>
<td>Question 1: This recommendation will be a challenging change in practice because ……</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GL 16 45</td>
<td>Question 3: Our trust has had experience of implementing this approach and would be willing to submit its experiences to the NICE shared learning database. Contact</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>General  General Prior to treatment all patients should have an HIV test</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>General  General Careful attention must be paid to potential drug interactions between antiretrovirals and chemotherapy.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Checklist for submitting comments**
- Use this comment form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Indicate which document you are commenting on by putting GL for the guideline, A, B, C or D for one of the underpinning evidence reports, or 1, 2, 3 or 4 for one of documents supplementary to the evidence reports.
- Include page and line number (not section number) of the text each comment is about.
- Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Underline and highlight any confidential information or other material that you do not wish to be made public.
Brain tumours (primary) and brain metastases in adults

Consultation on draft guideline – deadline for comments: 5pm on 23/02/2018, email: PrimaryBrainTumours@nice.org.uk

- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, comment forms do not include attachments such as research articles, letters or leaflets (for copyright reasons). We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.

You can see any guidance that we have produced on topics related to this guideline by checking NICE Pathways.

Note: We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.

Please return to: PrimaryBrainTumours@nice.org.uk